RxDoctor Payments Data

James Koch, MD

Neurology · Columbia, MONPI 1164625794

Payments from drug & device makers

$10,743in general payments, 2019–2025

Across 624 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$1K
  • Pfizer$508
  • EMD Serono, Inc.$508
  • Argenx US, Inc.$475
  • Sanofi$442
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$390%
  • Food & beverage$10,57998%
  • Education$1261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)97$1,621
Novartis51$1,022
Pfizer46$508
EMD Serono, Inc.30$508
Argenx US, Inc.23$475
Sanofi23$442
Teva Pharmaceuticals USA, Inc.24$368
Lilly USA, LLC18$367
Supernus Pharmaceuticals, Inc.55$339
UCB, Inc.14$326
Kyowa Kirin, Inc.16$249
Biohaven Pharmaceuticals, Inc.19$231
SK Life Science, Inc.10$228
Amgen11$213
AstraZeneca(2 entities)10$203
Lundbeck LLC10$181
ANI Pharmaceuticals, Inc.3$180
Amneal Pharmaceuticals LLC12$178
Genentech USA, Inc.10$177
Biogen8$159
Johnson & Johnson(2 entities)4$158
Bristol Myers Squibb7$133
Grifols USA, LLC5$131
Biohaven Pharmaceutical Holding Company Ltd.9$130
CSL Behring5$128
Otsuka America Pharmaceutical, Inc.7$122
Avanir Pharmaceuticals, Inc.6$118
Catalyst Pharmaceuticals, Inc.5$113
Neurocrine Biosciences, Inc.6$103
Banner Life Sciences, LLC5$100
Merz Pharmaceuticals, LLC4$96
Alnylam Pharmaceuticals Inc.4$88
Mallinckrodt Hospital Products Inc.4$86
Adamas Pharmaceuticals, Inc.5$85
Tanabe Pharma America, Inc.5$84
Medtronic(3 entities)4$80
Jazz Pharmaceuticals Inc.3$76
Harmony Biosciences LLC3$73
Acadia Pharmaceuticals Inc4$73
Eisai Inc.4$72
GE HealthCare2$66
Abbott3$60
Acorda Therapeutics, Inc3$56
Ipsen Biopharmaceuticals, Inc3$55
Mallinckrodt Enterprises LLC3$47
Almatica Pharma LLC2$45
Xeris Pharmaceuticals, Inc.2$38
Resmed Corp1$32
Averitas Pharma Inc.1$29
Amylyx Pharmaceuticals, Inc.1$27
Akcea Therapeutics, Inc.1$27
Boston Scientific1$25
Nevro Corp.1$25
Impel Pharmaceuticals Inc.1$24
Neurelis, Inc.1$22
TG Therapeutics, Inc.1$20
Kedrion Biopharma, Inc.1$18
Merck1$17
Sanofi-aventis U.S. LLC1$15
Octapharma USA, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,743 in reported general payments places this provider in the 70th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$244,028
Medicare patients
505
Services billed
17,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant25$33,265
Aimovig AutoinjectorErenumab-Aooe18$21,140
EliquisApixaban11$12,960
Carbidopa-LevodopaCarbidopa/Levodopa284$8,645
Gabapentin365$6,882
Pramipexole ErPramipexole Di-Hcl13$6,227
Rivastigmine36$5,770
Mycophenolate Mofetil41$4,063
Lacosamide59$3,021
Memantine Hcl182$2,987
Primidone141$2,722
Entacapone25$2,699
Pyridostigmine Bromide ErPyridostigmine Bromide14$2,629
Pyridostigmine Bromide37$2,607
AmantadineAmantadine Hcl18$2,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$1,621$33,26525 claims
PfizerEliquis$508$12,96011 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$178$6,67078 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 381 neurology providers in Missouri.

Other neurology in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →